Glitazones [3];Glitazone

Deutsche Medizinische Wochenschrift

Volumn 133, Issue 6, 2008, Pages 261-262

  Gundel, U F ^a  

^a NONE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLITAZONE DERIVATIVE; PIOGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT;

CARDIOVASCULAR RISK; DIABETES MELLITUS; DIABETIC PATIENT; DRUG EFFECT; HUMAN; LETTER; STATISTICAL SIGNIFICANCE; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; STATISTICAL ANALYSIS;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; THIAZOLIDINEDIONES; DATA INTERPRETATION, STATISTICAL;

EID: 39549100612     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1017510     Document Type: Letter

References (8)

1. Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study. Lancet 2005; 366 (9493): 1279-1289
2. Eckert S, Erdmann E, Lundershausen R et al. Konsensuspapier Pioglitazon in DMW. DMW 2007; 132: 2650-2653
3. Gaede P, Vedel P, Larsen N et al. Multifactorial intervention and cardiovscular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-93
4. Jackisch-Riemann A, Püntmann I, Mühlbauer B. Pioglitazon und die PROactive-Studie. Weniger Antworten als Fragen. Bremer Ärztejournal 2005; 12: 14-
5. Nathan DM. Finding new treatments for diabetes - how many, how fast, how good? N Engl J Med 2007; 356: 437-440
6. Rottlaender D, Michels G, Erdmann E et al. Therapie mit Glitazonen. DMW 2007; 132: 2629-2632
7. Sigal R, Malcolm J, Arnaut A. Prevention of cardiovascular events in diabetes. BMJ Clinical Evidence 2006; 02: 601-
8. Yki Yärvinnen H. The PROactive Study:some answers, many questions. Lancet 2005; 366: 1241-1242